These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37005966)

  • 1. Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.
    Yamauchi H; Toi M; Takayama S; Nakamura S; Takano T; Cui K; Campbell C; De Vos L; Geyer C; Tutt A
    Breast Cancer; 2023 Jul; 30(4):596-605. PubMed ID: 37005966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
    Geyer CE; Garber JE; Gelber RD; Yothers G; Taboada M; Ross L; Rastogi P; Cui K; Arahmani A; Aktan G; Armstrong AC; Arnedos M; Balmaña J; Bergh J; Bliss J; Delaloge S; Domchek SM; Eisen A; Elsafy F; Fein LE; Fielding A; Ford JM; Friedman S; Gelmon KA; Gianni L; Gnant M; Hollingsworth SJ; Im SA; Jager A; Jóhannsson ÓÞ; Lakhani SR; Janni W; Linderholm B; Liu TW; Loman N; Korde L; Loibl S; Lucas PC; Marmé F; Martinez de Dueñas E; McConnell R; Phillips KA; Piccart M; Rossi G; Schmutzler R; Senkus E; Shao Z; Sharma P; Singer CF; Španić T; Stickeler E; Toi M; Traina TA; Viale G; Zoppoli G; Park YH; Yerushalmi R; Yang H; Pang D; Jung KH; Mailliez A; Fan Z; Tennevet I; Zhang J; Nagy T; Sonke GS; Sun Q; Parton M; Colleoni MA; Schmidt M; Brufsky AM; Razaq W; Kaufman B; Cameron D; Campbell C; Tutt ANJ;
    Ann Oncol; 2022 Dec; 33(12):1250-1268. PubMed ID: 36228963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant Olaparib for Patients with
    Tutt ANJ; Garber JE; Kaufman B; Viale G; Fumagalli D; Rastogi P; Gelber RD; de Azambuja E; Fielding A; Balmaña J; Domchek SM; Gelmon KA; Hollingsworth SJ; Korde LA; Linderholm B; Bandos H; Senkus E; Suga JM; Shao Z; Pippas AW; Nowecki Z; Huzarski T; Ganz PA; Lucas PC; Baker N; Loibl S; McConnell R; Piccart M; Schmutzler R; Steger GG; Costantino JP; Arahmani A; Wolmark N; McFadden E; Karantza V; Lakhani SR; Yothers G; Campbell C; Geyer CE;
    N Engl J Med; 2021 Jun; 384(25):2394-2405. PubMed ID: 34081848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
    Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
    Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
    Domchek SM; Postel-Vinay S; Im SA; Park YH; Delord JP; Italiano A; Alexandre J; You B; Bastian S; Krebs MG; Wang D; Waqar SN; Lanasa M; Rhee J; Gao H; Rocher-Ros V; Jones EV; Gulati S; Coenen-Stass A; Kozarewa I; Lai Z; Angell HK; Opincar L; Herbolsheimer P; Kaufman B
    Lancet Oncol; 2020 Sep; 21(9):1155-1164. PubMed ID: 32771088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
    Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P
    Lancet Oncol; 2021 Dec; 22(12):1721-1731. PubMed ID: 34715071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies.
    Morganti S; Bychkovsky BL; Poorvu PD; Garrido-Castro AC; Weiss A; Block CC; Partridge AH; Curigliano G; Tung NM; Lin NU; Garber JE; Tolaney SM; Lynce F
    Oncologist; 2023 Jul; 28(7):565-574. PubMed ID: 37210568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations.
    Zettler CM; De Silva DL; Blinder VS; Robson ME; Elkin EB
    JAMA Netw Open; 2024 Jan; 7(1):e2350067. PubMed ID: 38170520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
    Robson ME; Im SA; Senkus E; Xu B; Domchek SM; Masuda N; Delaloge S; Tung N; Armstrong A; Dymond M; Fielding A; Allen A; Conte P
    Eur J Cancer; 2023 May; 184():39-47. PubMed ID: 36893711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
    Gelmon KA; Fasching PA; Couch FJ; Balmaña J; Delaloge S; Labidi-Galy I; Bennett J; McCutcheon S; Walker G; O'Shaughnessy J;
    Eur J Cancer; 2021 Jul; 152():68-77. PubMed ID: 34087573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
    Balmaña J; Fasching PA; Couch FJ; Delaloge S; Labidi-Galy I; O'Shaughnessy J; Park YH; Eisen AF; You B; Bourgeois H; Gonçalves A; Kemp Z; Swampillai A; Jankowski T; Sohn JH; Poddubskaya E; Mukhametshina G; Aksoy S; Timcheva CV; Park-Simon TW; Antón-Torres A; John E; Baria K; Gibson I; Gelmon KA;
    Breast Cancer Res Treat; 2024 Apr; 204(2):237-248. PubMed ID: 38112922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis.
    Im SA; Xu B; Li W; Robson M; Ouyang Q; Yeh DC; Iwata H; Park YH; Sohn JH; Tseng LM; Goessl C; Wu W; Masuda N
    Sci Rep; 2020 May; 10(1):8753. PubMed ID: 32472001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study.
    Alés-Martínez JE; Balmaña J; Sánchez-Rovira P; Salvador Bofill FJ; García Sáenz JÁ; Pimentel I; Morales S; Fernández-Abad M; Lahuerta Martínez A; Ferrer N; Zamora P; Bermejo B; Díaz-Redondo T; López-Ceballos MH; Galán M; Pérez-Escuredo J; Calabuig L; Sampayo M; Pérez-Garcia JM; Cortés J; Llombart-Cussac A
    Breast; 2024 Oct; 77():103780. PubMed ID: 39116683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance Olaparib for Germline
    Golan T; Hammel P; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O'Reilly EM; McGuinness D; Cui KY; Schlienger K; Locker GY; Kindler HL
    N Engl J Med; 2019 Jul; 381(4):317-327. PubMed ID: 31157963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
    Frenel JS; Kim JW; Aryal N; Asher R; Berton D; Vidal L; Pautier P; Ledermann JA; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Colombo N; Park-Simon TW; Tamura K; Sonke GS; Freimund AE; Lee CK; Pujade-Lauraine E
    Ann Oncol; 2022 Oct; 33(10):1021-1028. PubMed ID: 35772665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
    Vergote I; Ray-Coquard I; Anderson DM; Cantuaria G; Colombo N; Garnier-Tixidre C; Gilbert L; Harter P; Hettle R; Lorusso D; Mäenpää J; Marth C; Matsumoto K; Ouwens M; Poveda A; Raspagliesi F; Rhodes K; Rubio Pérez MJ; Shapira-Frommer R; Shikama A; Sikorska M; Moore K; DiSilvestro P
    Eur J Cancer; 2021 Nov; 157():415-423. PubMed ID: 34597975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Harnan S; Ren S; Thokala P; Wong R; Mukuria C; Green C; Pledge S; Tidy J
    Pharmacoeconomics; 2017 Jan; 35(1):97-109. PubMed ID: 27506954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial.
    Senkus E; Delaloge S; Domchek SM; Conte P; Im SA; Xu B; Armstrong A; Masuda N; Fielding A; Robson M; Tung N
    Int J Cancer; 2023 Aug; 153(4):803-814. PubMed ID: 36971103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.